Skip to content
Screener

Taysha Gene Therapies, Inc. TSHA Q2 2026 earnings

Reported August 11, 2026 · After market close

Revenue-
EPS-$0.13Miss by $0.02
EPS estimate-$0.11
“During the second quarter, we continued to execute against our clinical development strategy for TSHA-102 while advancing key commercial and manufacturing readiness initiatives in support of a potential BLA submission. The completion of dosing in our REVEAL pivotal and ASPIRE trials, as well as positive longer-term follow-up data from our REVEAL Phase 1/2 trials continues to strengthen our conviction in TSHA-102 as a potentially transformative therapy for this devastating disease with high unmet need. In addition, the favorable safety profile observed to date across a broad and diverse patient population supports TSHA-102's potential to safely deliver durable, meaningful functional benefits.”
Sean P. Nolan

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$755.6K
EPS estimate-$0.14

Financials

Q2 2026

Income statement

See full
Revenue--100%
Operating income-$47.3M-77.0%
Net income-$46.6M-73.5%
EPS (diluted)-$0.13-44.4%

Balance sheet

See full
Cash & equivalents$455.4M+45.6%
Total debt$56.7M-5.1%
Total equity$387.3M+55.7%
Total assets$470.4M+41.1%

Cash flow

See full
Operating cash flow-$40.4M-100%
Free cash flow-$40.4M-100%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.65B+109%
Enterprise value$1.25B+133%
P/S301.2×+203×

Profitability

See full
Operating margin-2,792.3%-9,679pp
Net margin-2,728%-9,858pp
FCF margin-2,417%-8,925pp

Returns & leverage

See full
Return on equity-47.1%-4.0pp
Debt / equity0.1×-0.1×
Current ratio17.8×+5.3×

FAQ

When did Taysha Gene Therapies, Inc. report Q2 2026 earnings?
Taysha Gene Therapies, Inc. (TSHA) reported Q2 2026 earnings on August 11, 2026 after market close.
What were Taysha Gene Therapies, Inc.'s Q2 2026 revenue and EPS?
Taysha Gene Therapies, Inc. reported revenue of - and eps of $-0.13 for Q2 2026.
Did Taysha Gene Therapies, Inc. beat estimates in Q2 2026?
EPS missed the consensus estimate of $-0.11 by $0.02.
How did Taysha Gene Therapies, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $2.0M a year earlier and eps declined 44.4% from $-0.09.
Where can I find Taysha Gene Therapies, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-344594) and the 10-Q periodic report (0001193125-26-344610) directly on SEC EDGAR. The filing index links above go to sec.gov.